News

The discovery of micro-sized RNA molecules (miRNAs)—a breakthrough described as "the biological equivalent of dark matter, all around us but almost escaping detection"—earned the coveted 2001-2002 AAAS Newcomb Cleveland Prize.

When the $100M HapMap project was announced late last year, it stoked a decades-long debate surrounding the “common-disease, common variant” hypothesis. Can hunting for links between common genetic variants and common diseases help reveal why some individuals are more susceptible to common diseases like diabetes and hypertension than others?

Whitehead Institute recently released for public use a new computational tool that can help researchers more precisely silence gene function, streamlining drug discovery and disease research efforts.

Save the dates for this year's spring lecture series at the Boston Museum of Science, March 5, 12, and 19. This year's series, "Beyond the Double Helix," will feature Whitehead researchers who are taking a variety of new approaches to elucidate how genes and proteins coordinate cell activity and, in some cases, cause disease.

On January 1, the Whitehead Institute welcomed Lydia Villa-Komaroff and Maxine Singer to its leadership ranks. Villa-Komaroff was named Vice President of Research and Chief Operating Officer for the Whitehead Institute; Singer assumed the Chairmanship of the Institute's Board of Directors.

Massachusetts can seize the opportunity to achieve global leadership in the life-sciences economy if the Commonwealth takes a more active state role in the promotion and support of biotechnology, according to a new report issued this month by the Massachusetts Biotechnology Council (MBC) and the Boston Consulting Group.

What can a humble seashell tell us about how to build biocomputers at the nanoscale level—50,000 times smaller than the width of a human hair? Plenty, according to Angela M. Belcher, Professor of Materials Science and Engineering and Bioengineering at the Massachusetts Institute of Technology.

The Whitehead Institute Center for Genome Research and the International Mouse Genome Sequencing Consortium today announced the publication of the genetic blueprint of a mouse together with insights gleaned from comparing mouse and human sequences.

Whitehead Institute Member Richard Young's lab has discovered a unique approach to vaccine development, which is now in phase II and III human clinical trials for the cancer-causing human papilloma virus.

In today’s research arena, success requires biologists, physicians, chemists, mathematicians, and bioinformatics specialists to funnel unique expertise into shared projects. At Whitehead, interdisciplinary collaboration has fostered discoveries at the intersection of what were once disparate disciplines and has inspired the Institute to aggressively recruit diverse talent to the lab.